Our focus defines boehringer ingelheims road to innovation and growth for the years to come. It is our companys global vision, that we apply to our daily work - wherever in the global boehringer ingelheim-landscape this may be.
Our focus our focus is on improving the lives of people and communities experiencing poverty and trauma. Here are the areas we will be exploring more in the course of our strategy for 2020-2030. Poverty and trauma (especially in childhood) can affect peoples wellbeing and life chances significantly.
The undp green commodities programme exists to improve the national, economic, social and environmental performance of agricultural commodity sectors. In 2010, undp launched the gcp in recognition of the importance of global agricultural commodities in achieving the sdgs, with a mission to improve the lives of farmers and their communities.
Our Focus – Medusa Capital
The build-to-rent sector is estimated to be worth 60bn in the next 10 years. Medusa capitals build-to-rent cell originated out of an opportunity which exists in private rented sector (prs) to build sustainable, quality, long-term housing within the build-to-rent market. The cells focus will be to become involved in build-to-rent.
We have over a decade of experience in delivering digital leadership across all roles from board level to functional management. We curate boards and executive teams to drive growth and transformation. We appoint both senior experienced executives as well as first time ceo and board members, bringing the right experiences and fresh perspective.
Orphazyme is a late-stage biopharmaceutical company pioneering the heat shock protein (hsp) response for the treatment of neurodegenerative orphan diseases. We have clinical trial programs underway in four areas to explore the potential of our lead investigational treatment, arimoclomol. Heat shock proteins, such as heat shock protein 70 (hsp70), are a group of endogenous stress.